Lumefantrine CO-artemether
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Lumefantrine CO-artemether
- Structure (SMILES)
- C(CN(CCCC)CCCC)(O)c1cc(Cl)cc/2c1-c3c(cc(cc3)Cl)\C2=C\c4ccc(Cl)cc4.CO[C@@H]1[C@H](C)[C@@]2([H])[C@@]34OO[C@@](C)(O[C@@]3([H])O1)CC[C@@]4([H])[C@H](C)CC2.C(CN(CCCC)CCCC)(O)c1c-2c(/C(=C\c3ccc(cc3)Cl)/c4c2ccc(c4)Cl)cc(Cl)c1.C(CN(CCCC)CCCC)(O)c1c-2c(/C(=C\c3ccc(cc3)Cl)/c4c2ccc(c4)Cl)cc(Cl)c1.C(CN(CCCC)CCCC)(O)c1c-2c(/C(=C\c3ccc(cc3)Cl)/c4c2ccc(c4)Cl)cc(Cl)c1.C(CN(CCCC)CCCC)(O)c1c-2c(/C(=C\c3ccc(cc3)Cl)/c4c2ccc(c4)Cl)cc(Cl)c1.C(CN(CCCC)CCCC)(O)c1c-2c(/C(=C\c3ccc(cc3)Cl)/c4c2ccc(c4)Cl)cc(Cl)c1
- AL (Coartem)
- al coartem
- coartem
- Coartem
- Coartem® (artemether lumefantrine)
- cpg 56697
- CPG-56697
- fixed 6 1 lumefantrine mixture with artemether
- FIXED 6:1 LUMEFANTRINE MIXTURE WITH ARTEMETHER
- lumefantrine co artemether
- lumefantrine co artemether mi
- Lumefantrine co-artemether
- LUMEFANTRINE CO-ARTEMETHER [MI]
- riamet
- Riamet
- Riamet®
- SoC (Coartem)
- CAS registry numbers
- 141204-94-6
- ChEMBL ID
- CHEMBL4297927
- InChIKey
- VZQXHIJHMCHBNW-UFIXNTOBSA-N
- PubChem compound IDs
- 6450800
- FDA ingredient codes (UNII)
- 5T2U51A0MW
- First in class
- No
- Orphan designation
- No
- Condition
- Malaria
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007444
- Highest recorded phase
- 3
- Condition identifier
- HP_0001945
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005136
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005249
- Condition identifier
- MONDO_0005920
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005921
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- Event
- asthenia
- Reports
- 16
- Reporting signal score
- 11.6607
- Event
- autoimmune haemolytic anaemia
- Reports
- 2
- Reporting signal score
- 5.57369
- Event
- blood bilirubin increased
- Reports
- 5
- Reporting signal score
- 7.71995
- Event
- cerebral malaria
- Reports
- 2
- Reporting signal score
- 15.1758
- Event
- chromaturia
- Reports
- 4
- Reporting signal score
- 7.72294
- Event
- cold agglutinins positive
- Reports
- 1
- Reporting signal score
- 5.61027
- Event
- coombs negative haemolytic anaemia
- Reports
- 3
- Reporting signal score
- 17.1748
- Event
- coombs positive haemolytic anaemia
- Reports
- 5
- Reporting signal score
- 26.4748
- Event
- coombs test negative
- Reports
- 1
- Reporting signal score
- 6.99764
- Event
- haemolysis
- Reports
- 5
- Reporting signal score
- 14.8346
- Event
- haemolytic anaemia
- Reports
- 44
- Reporting signal score
- 206.537
- Event
- haptoglobin decreased
- Reports
- 2
- Reporting signal score
- 8.63853
- Event
- hepatocellular injury
- Reports
- 6
- Reporting signal score
- 11.0422
- Event
- hookworm infection
- Reports
- 1
- Reporting signal score
- 6.79704
- Event
- infection protozoal
- Reports
- 1
- Reporting signal score
- 6.79704
- Event
- jaundice acholuric
- Reports
- 2
- Reporting signal score
- 12.5069
- Event
- labia enlarged
- Reports
- 1
- Reporting signal score
- 6.10444
- Event
- malaria
- Reports
- 3
- Reporting signal score
- 14.0335
- Event
- malaria antibody test positive
- Reports
- 1
- Reporting signal score
- 8.09603
- Event
- nematodiasis
- Reports
- 1
- Reporting signal score
- 7.80838
- Event
- plasmodium falciparum infection
- Reports
- 6
- Reporting signal score
- 43.0275
- Event
- plasmodium malariae infection
- Reports
- 1
- Reporting signal score
- 7.40299
- Event
- pyrexia
- Reports
- 18
- Reporting signal score
- 12.6954
- Event
- skin swelling
- Reports
- 2
- Reporting signal score
- 6.47067
- Event
- swelling face
- Reports
- 7
- Reporting signal score
- 9.76099
And 1 more, listed on the interactive page.
- NCT00484900
- NCT03167242
- NCT04546633
- NCT05750628
- NCT05842954
- NCT02627456
- NCT02942277
- NCT03334747
- NCT03952650
- NCT04675931
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 0
- Antimalarials
Related records
Trials (202)
- "Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
- 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
- A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis
- A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
- A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
- A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19
- A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
- A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
- A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
- A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
- A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
- A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
- A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
- A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
- A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
In development for (2)
- Malaria Phase 2
- Plasmodium falciparum malaria Phase 3